CORDIS · 212114 · FP7
SLHC-PP Preparatory Phase of the Large Hadron Collider Upgrade
Coordinator: ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE (CH)
The Large Hadron Collider upgrade (SLHC) is the project with highest priority in “The European strategy for particle physics” document, unanimously approved by the CERN Council in July 2006. The SLHC, with expected 1 B€ budget, includes the upgrade of specific elements of the LHC accelerator, major upgrades in the accelerator injector complex, as well as upgrades to the two high-luminosity experiments ATLAS and CMS. It will result in a tenfold increase of the LHC luminosity. Thus the SLHC will remain the most powerful particle accelerator in the world in the next two decades. The Preparatory …
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €5.2M toward a total project budget of €15.6M — a funding rate of 33%, with the remainder covered by the consortium partners. The project runs over approximately 3 years from 2008-04-01 to 2011-03-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- IABC PROGRAMME — iABC Programme115721 · FP7 · €24.3M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-CSA-Infra funding scheme.
- What is the EU contribution?
- The European Commission contributes €5.2M toward a total project budget of €15.6M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by ORGANISATION EUROPEENNE POUR LA RECHERCHE NUCLEAIRE (CH).
- What is the project timeline?
- The project runs from 2008-04-01 to 2011-03-31 — approximately 3 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 212114.